Innovation Pharmaceuticals Inc (IPIX)

[georgejjl]

Additional formulation work is planned for the inhaled delivery of brilacidin for prophylactic use, toward controlling infection in the nasal passage and lungs by leveraging brilacidin’s ability to inhibit SARS-CoV-2 by disrupting viral integrity and impacting viral entry. Such development efforts, if successful, may enable brilacidin to emerge as a particularly effective and differentiated antiviral by preventing and/or decreasing early infectivity due to SARS-CoV-2.

Clearly, an effective COVID-19 therapeutic (or therapeutics in combination) ideally would control both viral load and the corresponding inflammatory damage due to SARS-CoV-2,93 and mitigate bacterial co-infections. Exhibiting three-in-one properties—antiviral, immuno/anti-inflammatory, and antibacterial—brilacidin is being developed for the intravenous treatment of COVID-19 in hospitalized patients and may be able to address different disease parameters within the one therapeutic treatment.

https://www.biorxiv.org/content/10.1101/2020.10.29.352450v1.full

Good luck and GOD bless,